Doxorubicin With Upfront Dexrazoxane for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma
Active, not recruiting
Washington University School of Medicine
Phase 2
2016-02-22
The purpose of this research study is to look at whether giving a drug called dexrazoxane
with standard of care doxorubicin affects the progression of the disease. Dexrazoxane is
often given at the same time as doxorubicin to help reduce the incidence and severity of
disease of the heart muscle (which can be caused by doxorubicin).
In January 2019 Eli Lilly and Company reported that the results of the Phase 3 study of
olaratumab (Lartruvo), in combination with doxorubicin in patients with advanced or
metastatic soft tissue sarcoma, did not confirm the clinical benefit of olaratumab in
combination with doxorubicin as compared to doxorubicin alone. Therefore olaratumab is being
removed from the front line standard of care regimen. Amendment #9 was made to the protocol
to reflect these changes to the standard of care treatment.
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Withdrawn
Janssen Scientific Affairs, LLC
Phase 1
2019-06-01
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D)
and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or
recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.
Trabectedin, Doxorubicin and Olaratumab in Patients With Metastatic or Recurrent Leiomyosarcoma
Withdrawn
University of Miami
Phase 1
2019-06-01
This study seeks to determine if addition of trabectedin (T) to combination doxorubicin (D)
and olaratumab (O), is feasible and tolerable with antitumor activity in metastatic or
recurrent Leiomyosarcomas (LMS) patients who have limited therapeutic options.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.